LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 29

Search options

  1. Article: [Possibilities of Predicting Peak Oxygen Consumption in Patients With Chronic Heart Failure According to the 6‑Minute Walk Test].

    Begrambekova, Yu L / Fedotov, D A / Karanadze, N A / Lelyavina, T A / Bortsova, M A / Orlova, Ya A

    Kardiologiia

    2024  Volume 64, Issue 2, Page(s) 34–42

    Abstract: Aim: To determine the correlation between the results of the 6-minute walk test (6MWT) and peak oxygen consumption (VO2peak) for populations of patients with chronic heart failure with pronounced clinical and demographic differences; to study a ... ...

    Abstract Aim: To determine the correlation between the results of the 6-minute walk test (6MWT) and peak oxygen consumption (VO2peak) for populations of patients with chronic heart failure with pronounced clinical and demographic differences; to study a possibility of indirect measurement of VO2peak based on the results of 6MWT using the formulas available from the literature.
    Material and methods: Two databases were analyzed: 50 patients included in the AEROFIT study (group A), and 31 patients from the Almazov National Medical Research Center (group B). The inclusion criteria were the availability of data from the cardiopulmonary stress test and the 6MWT. The possibility of predicting VO2peak was calculated based on the results of 6MWT using the formulas reported in the literature (L. P. Cahalin et al., 1996; R. M. Ross et al., 2010; R. A. Adedoyin et al., 2010). The predictive accuracy of the models was assessed using the coefficient of determination (R2). The relationship between functional and clinical-demographic indicators was assessed using the Pearson or Spearman correlation analysis.
    Results: The study groups differed significantly in all parameters, except for the proportion of men and the mean VO2peak. Group B patients were 20 years younger than group A patients, had a lower left ventricular ejection fraction (24.06±7.75 and 41.52±10.48 %, respectively; p<0.001), and covered a 130 m shorter distance in the 6MWT. Despite the absence of a significant difference in VO2peak between groups A and B (13.6 and 13.1 ml / kg / min, respectively; p=0.6581), 61 % of group B patients and 20% of group A belonged to Weber functional class IV. In group A, the 6MWT distance correlated closely with VO2peak (R=0.78; p<0.01) and weakly with age (R=0.4) and body mass index (R=0.3). In group B, the 6MWT distance correlated only with VO2peak (R=0.77; p<0.01). For group A, the R.M. Ross et al. model demonstrated high accuracy in determining the mean VO2peak value with a 0.06% prediction error normalized to measured VO2peak. For group B, none of the models showed satisfactory predictive accuracy. The Ross and Cahalin models showed the best coefficients of determination for groups A and B: Group A, Ross et al. (R2=0.58) and Cahalin et al. (R2=0.59); Group B, Ross et al. (R2=0.59) and Cahalin et al. (R2=0.6).
    Conclusion: In two groups of patients with a statistically insignificant difference in the mean values of VO2peak, the mean values of 6MWT distance were significantly different, although these indicators correlated closely. The VO2peak prediction models showed satisfactory accuracy for estimation of mean VO2, but poor accuracy for estimation of individual values. A better predictive accuracy is determined by similar clinical and demographic characteristics between the training and testing populations, and likely also by models based on larger, more diversified populations.
    MeSH term(s) Male ; Humans ; Walk Test ; Stroke Volume ; Ventricular Function, Left ; Oxygen Consumption ; Exercise Test/methods ; Chronic Disease ; Heart Failure/diagnosis
    Language Russian
    Publishing date 2024-02-29
    Publishing country Russia (Federation)
    Document type English Abstract ; Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18087/cardio.2024.2.n2551
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: [Expert opinion. Spironolactone: a new twist on an old story].

    Orlova, Ya A / Begrambekova, Yu L / Plisuk, A G

    Kardiologiia

    2021  Volume 61, Issue 10, Page(s) 99–103

    Abstract: The article presents recent data on possibilities of a broader use of mineralocorticoid receptor antagonists for existing indications and of expanding indications for the use of this pharmaceutical group in the context of the novel coronavirus infection ... ...

    Abstract The article presents recent data on possibilities of a broader use of mineralocorticoid receptor antagonists for existing indications and of expanding indications for the use of this pharmaceutical group in the context of the novel coronavirus infection COVID-19. The authors discussed prospects for expanded detection of aldosteronism using a new diagnostic approach, including an additional evaluation of blood pressure response to spironolactone.
    MeSH term(s) COVID-19 ; Expert Testimony ; Humans ; Hypertension ; Mineralocorticoid Receptor Antagonists ; SARS-CoV-2 ; Spironolactone
    Chemical Substances Mineralocorticoid Receptor Antagonists ; Spironolactone (27O7W4T232)
    Language Russian
    Publishing date 2021-10-30
    Publishing country Russia (Federation)
    Document type Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18087/cardio.2021.10.n1734
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: [Red cell distribution width as a predictor of impaired exercise capacity in patients with heart failure].

    Karanadze, N A / Begrambekova, Yu L / Borisov, E N / Orlova, Ya A

    Kardiologiia

    2022  Volume 62, Issue 4, Page(s) 30–35

    Abstract: Aim    To test a hypothesis that increased values of red cell distribution width (RDW) in patients with chronic heart failure (CHF) can be related with low exercise tolerance.Material and methods    102 patients were evaluated who had CHF with mid-range ... ...

    Abstract Aim    To test a hypothesis that increased values of red cell distribution width (RDW) in patients with chronic heart failure (CHF) can be related with low exercise tolerance.Material and methods    102 patients were evaluated who had CHF with mid-range and reduced left ventricular ejection fraction (LV EF) without anemia (72% men, mean age 66±10.2 years). Cardiopulmonary stress test (CPST), echocardiography, 6‑min walk test (6MWT), blood count, and measurements of N-terminal pro-brain natriuretic peptide (NT-pro-BNP) and serum iron were performed.Results    The average LV EF was 39±8.7 %; the peak oxygen consumption (VO2peak) was 13.7±4.8 ml /kg /min; and the median NT-pro-BNP was 595.3 pg /ml (Q1-3 1443-2401). RDW variables, including the RDW coefficient of variation (RDW-CV) and RDW standard deviation (RDW-SD), were not significantly related with serum iron or hemoglobin concentrations. A one-factor linear regression analysis showed a significant correlation of VO2peak with RDW-SD (р=0.039). A multivariate linear regression analysis with adjustments for LV EF, hemoglobin concentration, and age did not reveal any significant correlation of VO2peak with RDW variables. The distance covered in the 6MWT was significantly associated with RDW-CV both in the one-factor analysis and with adjustments for LV EF, hemoglobin and serum iron concentrations, and age.Conclusion    This study showed that high RDW values in CHF patients without anemia predicted low exercise tolerance regardless of the age, LV systolic function, and hemoglobin and serum iron concentrations. A 16% increase in RDW-CV significantly decreased the likelihood of covering a distance longer than 360 m during 6 min.
    MeSH term(s) Aged ; Chronic Disease ; Erythrocyte Indices ; Exercise Tolerance ; Female ; Heart Failure ; Hemoglobins ; Humans ; Iron ; Male ; Middle Aged ; Natriuretic Peptide, Brain ; Peptide Fragments ; Stroke Volume ; Ventricular Function, Left
    Chemical Substances Hemoglobins ; Peptide Fragments ; Natriuretic Peptide, Brain (114471-18-0) ; Iron (E1UOL152H7)
    Language Russian
    Publishing date 2022-04-30
    Publishing country Russia (Federation)
    Document type Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18087/cardio.2022.4.n1813
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: [No title information]

    Begrambekova, Yu L / Karanadze, N A / Orlova, Ya A

    Kardiologiia

    2019  Volume 59, Issue 2S, Page(s) 15–24

    Abstract: The review discusses mechanisms for the development of the pathology of the respiratory system in patients with CHF, such as various types of periodic respiration, pulmonary hypertension due to the pathology of the left chambers of the heart, and ... ...

    Title translation Alterations of the respiratory system in heart failure.
    Abstract The review discusses mechanisms for the development of the pathology of the respiratory system in patients with CHF, such as various types of periodic respiration, pulmonary hypertension due to the pathology of the left chambers of the heart, and remodeling of the respiratory musculature. The role of chemo- and baroreceptors of the carotid zone, as well as the hyperactivation of the respiratory muscle metaboreflex in the development of the pathology of the respiratory system, and the mediated exacerbation of CHF are discussed.
    MeSH term(s) Heart ; Heart Failure ; Humans ; Respiratory System
    Language Russian
    Publishing date 2019-03-07
    Publishing country Russia (Federation)
    Document type Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18087/cardio.2626
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: [Thiazide and Thiazide-Like Diuretics in Therapy of Arterial Hypertension].

    Orlova, Ya A / Kurlykina, N V / Seredenina, E M

    Kardiologiia

    2019  Volume 59, Issue 11, Page(s) 84–94

    Abstract: The review presents results of clinical studies of efficacy and safety of thiazide and thiazide-like diuretics in the treatment of patients with arterial hypertension. In this work we have compared the role of diuretics in modern clinical recommendation ... ...

    Abstract The review presents results of clinical studies of efficacy and safety of thiazide and thiazide-like diuretics in the treatment of patients with arterial hypertension. In this work we have compared the role of diuretics in modern clinical recommendation on control of arterial pressure, and assessed in comparative aspect metabolic effects of thiazide-like diuretics.
    MeSH term(s) Diuretics ; Humans ; Hypertension ; Sodium Chloride Symporter Inhibitors ; Thiazides
    Chemical Substances Diuretics ; Sodium Chloride Symporter Inhibitors ; Thiazides
    Language Russian
    Publishing date 2019-12-13
    Publishing country Russia (Federation)
    Document type Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18087/cardio.2019.11.2653
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: [Association of AGT, ACE, NOS3, TNF, MMP9, CYBA polymorphism with subclinical arterial wall changes].

    Akopyan, A A / Kirillova, K I / Strazhesko, I D / Samokhodskaya, L M / Orlova, Ya A

    Kardiologiia

    2021  Volume 61, Issue 3, Page(s) 57–65

    Abstract: Aim    Activation of the renin-angiotensin-aldosterone system, decreased nitric oxide production, chronic inflammation, and oxidative stress result in subclinical changes in the arterial wall, which favor the development of cardiovascular diseases (CVD). ...

    Abstract Aim    Activation of the renin-angiotensin-aldosterone system, decreased nitric oxide production, chronic inflammation, and oxidative stress result in subclinical changes in the arterial wall, which favor the development of cardiovascular diseases (CVD). The effect of allelic gene variants that encode the proteins participating in pathogenetic pathways of age-associated diseases with subclinical changes in the arterial wall [increased pulse wave velocity (PWV), increased intima-media thickness, endothelial dysfunction (ED), presence of atherosclerotic plaques (ASP)] are understudied. This study analyzed the relationship between AGT, ACE, NOS3 TNF, MMP9, and CYBA gene polymorphism and the presence of subclinical changes in the arterial wall, including the dependence on risk factors for CVD, in arbitrarily healthy people of various age.Material and methods    The relationship of polymorphisms с.521С>Т of AGT gene, Ins>Del of AСE gene, с.894G>T of NOS3 gene, - 238G>A of TNF gene, - 1562С>T of MMP9 gene, and c.214Т>С of CYBA gene with indexes of changes in the arterial wall and risk factors for CVD was studied in 160 arbitrarily healthy people by building models of multiple logistic regression and also by analyzing frequencies of co-emergence of two signs with the Pearson chi-squared test (χ2) and Fisher exact test.Results    The DD-genotype of Ins>Del ACE gene polymorphism was correlated with increased PWV (p=0.006; odds ratio (OR) =3.41, 95 % confidence interval (CI): 1.48-8.67) and ED (p=0.014; OR=2.60, 95 % CI: 1.22-5.68). The GG genotype of с.894G>T NOS3 gene polymorphism was correlated with ED (p=0.0087; OR=2.65, 95 % CI: 1.26-5.72); the ТТ-genotype of с.894G>T NOS3 gene polymorphism was correlated with ASP (p=0.033; OR=0.034, 95 % CI: 0.001-0.549).Conclusion    Polymorphic variants of AСE and NOS3 genes correlated with ED, increased arterial wall stiffness, and the presence of subclinical changes in the arterial wall.
    MeSH term(s) Alleles ; Carotid Intima-Media Thickness ; Humans ; Matrix Metalloproteinase 9 ; NADPH Oxidases ; Nitric Oxide Synthase Type III/genetics ; Polymorphism, Genetic ; Pulse Wave Analysis
    Chemical Substances NOS3 protein, human (EC 1.14.13.39) ; Nitric Oxide Synthase Type III (EC 1.14.13.39) ; NADPH Oxidases (EC 1.6.3.-) ; CYBA protein, human (EC 1.6.3.1) ; MMP9 protein, human (EC 3.4.24.35) ; Matrix Metalloproteinase 9 (EC 3.4.24.35)
    Language Russian
    Publishing date 2021-03-30
    Publishing country Russia (Federation)
    Document type Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18087/cardio.2021.3.n1212
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: The Burden of Residual SymptOms That Complicate the Life of Patients Who Have Suffered a new Coronavirus Infection (THROW study).

    Orlova, Ya A / Mareev, Yu V / Mareev, V Yu / Plisyk, A G / Begrambekova, Yu L / Akopyan, Z A / Sakaeva, D M / Loginova, D D / Shurygina, A S / Kamalov, A A

    Kardiologiia

    2022  Volume 62, Issue 10, Page(s) 26–34

    Abstract: Aim      To evaluate the prevalence of residual symptoms in patients hospitalized for novel coronavirus infection at 8 months after discharge and the severity of such symptoms depending on demographic characteristics, concurrent diseases, and specific ... ...

    Abstract Aim      To evaluate the prevalence of residual symptoms in patients hospitalized for novel coronavirus infection at 8 months after discharge and the severity of such symptoms depending on demographic characteristics, concurrent diseases, and specific features of the acute period of COVID-19.Material and methods  This study included the patients who were managed for novel coronavirus infection in a COVID-19 hospital and provided their consent to participate in the study (98 patients). At 8 months after discharge from the hospital, a structured telephone interview was performed.Results Only 40 % of patients treated for COVID-19 did not have any complaints at 8 months after discharge from the hospital. The most frequent complaints in the long term were fatigue (30.5 %), weakness (28.4 %), shortness of breath (23.2 %), arthralgia (22.1 %), myalgia (17.9 %), and anosmia (15.8 %). The background of chronic diseases and obesity, percentage of lung damage according to CT data, and the requirement for oxygen support during the acute period in our sample were not related with the presence of symptoms in the long term. The presence and severity of symptoms during the long term were not determined by the clinical condition, volume of lung damage, or requirement for oxygen support but were related with the gender and severity of inflammation upon admission.Conclusion      Independent predictors for persistence of symptoms in the patient sample with severe novel coronavirus infection during the long term included chest and joint pain during the stay in the hospital, female gender, and increased levels of C-reactive protein upon admission.
    MeSH term(s) Humans ; Female ; COVID-19/complications ; COVID-19/epidemiology ; Disease Progression ; Patient Discharge ; Hospitalization ; Oxygen
    Chemical Substances Oxygen (S88TT14065)
    Language English
    Publishing date 2022-10-30
    Publishing country Russia (Federation)
    Document type Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18087/cardio.2022.10.n2198
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article: [No title information]

    Kamalov, A A / Nesterova, O Yu / Orlova, Ya A / Mareev, V Yu / Mareev, Yu V / Pavlova, Z Sh / Okhobotov, D A / Strigunov, A A / Vasilevsky, R P / Nesuk, O M / Demkin, V V

    Urologiia (Moscow, Russia : 1999)

    2022  , Issue 5, Page(s) 15–22

    Abstract: Purpose: Assessment of COVID-19 incidence and hospitalization rate of male patients with prostatic hyperplasia depending on the intake of 5-alpha-reductase inhibitors (5-ARI).: Materials and methods: In our study, electronic medical records of 1678 ... ...

    Abstract Purpose: Assessment of COVID-19 incidence and hospitalization rate of male patients with prostatic hyperplasia depending on the intake of 5-alpha-reductase inhibitors (5-ARI).
    Materials and methods: In our study, electronic medical records of 1678 patients with prostatic hyperplasia were analyzed. 1490 men aged 71 (64-76) years were selected for final analysis. Vaccination against COVID-19 was carried out in 730 patients (49%). Treatment with 5-ARI inhibitors was carried out in 269 (18.1%) patients.
    Results: Among 1490 included patients 790 (53%) had COVID- 19 while 360 (45.7%) of them required hospitalization. During the multivariate analysis, only two factors were associated with the risk of COVID-19 in the cohort studied: vaccination (odds ratio (OR) =0.095; 95% confidence interval (CI) 0.074-0.122), i.e. a 90.5% chance reduction, p<0.001) and the fact of taking 5-ARI (OR=0.235; 95%CI=0.165-0.335; p<0.001), i.e. a 76.5% chance reduction. The duration of 5-ARI therapy was not associated with the incidence of new coronavirus infection. The severe course of COVID-19 which required hospitalization was positively associated with age (p=0.025) and the presence of coronary artery disease (p=0.004); and negatively associated with the frequency of vaccination (p<0.001) and treatment of 5-ARI (3.1% vs. 11.6%, p<0.001). In a multivariate analysis of outpatient patients with prostatic hyperplasia who had COVID-19, 5-ARI intake (OR=0.240; 95% CI 0.122-0.473; p<0.001) and vaccination (OR = 0.570; 95% CI 0.401-0.808; p=0.002). The factors associated with increased chances of hospitalization due to the severe course of COVID-19 were coronary heart disease (+43.8%, p=0.019) and older age (+1.7% by one year, p=0.046).
    Conclusion: Taking 5-ARI, along with vaccination in patients with prostatic hyperplasia is a protective factor for morbidity and the severity of COVID-19.
    MeSH term(s) Humans ; Male ; Prostatic Hyperplasia/epidemiology ; Prostatic Hyperplasia/therapy ; Prostatic Hyperplasia/complications ; COVID-19/epidemiology ; COVID-19/therapy ; 5-alpha Reductase Inhibitors ; Cohort Studies ; Incidence
    Chemical Substances 5-alpha Reductase Inhibitors
    Language Russian
    Publishing date 2022-10-30
    Publishing country Russia (Federation)
    Document type English Abstract ; Journal Article
    ZDB-ID 43204-0
    ISSN 1728-2985 ; 0042-1154
    ISSN 1728-2985 ; 0042-1154
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Hydroxychloroquine in patients with novel coronavirus infection (COVID-19): a case-control study.

    Kamalov, A A / Mareev, V Yu / Orlova, Ya A / Plisyk, A G / Akopyan, Z A / Mareev, Yu V / Mershina, E A / Begrambekova, Yu L / Pakhomov, P V

    Kardiologiia

    2021  Volume 61, Issue 2, Page(s) 28–39

    Abstract: Actuality One of the most widely discussed treatments for patients with COVID-19, especially at the beginning of the epidemy, was the use of the antimalarial drug hydroxychloroquine (HCQ). The first small non-randomized trials showed the ability of HCQ ... ...

    Abstract Actuality One of the most widely discussed treatments for patients with COVID-19, especially at the beginning of the epidemy, was the use of the antimalarial drug hydroxychloroquine (HCQ). The first small non-randomized trials showed the ability of HCQ and its combination with azithromycin to accelerate the elimination of the virus and ease the acute phase of the disease. Later, large, randomized trials did not confirm it (RECOVERY, SOLIDARITY). This study is a case-control study in which we compared patients who received and did not receive HCQ.Material and Methods 103 patients (25 in the HCQ treatment group and 78 in the control group) with confirmed COVID-19 (SARS-CoV-2 virus RNA was detected in 26 of 73 in the control group (35.6%) and in 10 of 25 (40%) in the HCQ group) and in the rest - a typical picture of viral pneumonia on multislice computed tomography [MSCT]) were included in the analysis. The severity of lung damage was limited to stages I-II, the CRP level should not exceed 60 mg/dL, and oxygen saturation in the air within 92-98%. We planned to analysis the duration of treatment of patients in the hospital, the days until the normalization of body temperature, the number of points according to the original SHOCS-COVID integral scale, and changes in its components (C-reactive protein (CRP), D-dimer, and the percentage of lung damage according to MSCT).Results Analysis for the whole group revealed a statistically significant increase in the time to normalization of body temperature from 4 to 7 days (by 3 days, p<0.001), and the duration of hospitalization from 9.4 to 11.8 days (by 2.4 days, p=0.002) when using HCQ in comparison with control. Given the incomplete balance of the groups, the main analysis included 46 patients who were matched by propensity score matching. The trend towards similar dynamics continued. HCQ treatment slowed down the time to normalization of body temperature by 1.8 days (p=0.074) and lengthened the hospitalization time by 2.1 days (p=0.042). The decrease in scores on the SHOCS -COVID scale was statistically significant in both groups, and there were no differences between them (delta - 3.00 (2.90) in the HCQ group and - 2.69 (1.55) in control, p=0.718). At the same time, in the control group, the CRP level returned to normal (4.06 mg/dl), and with the use of GC, it decreased but remained above the norm (6.21 mg/dl, p=0.05). Side effects requiring discontinuation of treatment were reported in 3 patients in the HCQ group and none in the control group.Conclusion We have not identified any positive properties of HCQ and its ability to influence the severity of COVID-19. This antimalarial agent slows down the normalization of the body's inflammatory response and lengthens the time spent in the hospital. HCQ should not be used in the treatment of COVID-19.
    MeSH term(s) COVID-19/drug therapy ; Case-Control Studies ; Coronavirus Infections ; Humans ; Hydroxychloroquine ; SARS-CoV-2 ; Treatment Outcome
    Chemical Substances Hydroxychloroquine (4QWG6N8QKH)
    Language English
    Publishing date 2021-03-02
    Publishing country Russia (Federation)
    Document type Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18087/cardio.2021.2.n1548
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: [Cardiovascular effects of omega-3 polyunsaturated fatty acids: position of omega-3 polyunsaturated fatty acids in Russian and international guidelines. Council of Experts].

    Mareev, Yu V / Ezhov, M V / Villevalde, S V / Alieva, A S / Obrezan, A G / Tarasov, A V / Panov, A V / Konstantinov, V O / Sergienko, I V / Arutiunov, A G / Batiushin, M M / Gurevich, V S / Tarlovskaya, E I / Koziolova, N A / Gromova, O A / Orlova, Ya A / Arutyunov, G P / Mareev, V Yu

    Kardiologiia

    2023  Volume 63, Issue 2, Page(s) 11–18

    Abstract: This Expert Council focuses on the meta-analysis of studies on the risk of atrial fibrillation (AF) in patients taking omega-3 polyunsaturated fatty acids (PUFA) and of data on the omega-3 PUFA treatment in patients with cardiovascular and kidney ... ...

    Abstract This Expert Council focuses on the meta-analysis of studies on the risk of atrial fibrillation (AF) in patients taking omega-3 polyunsaturated fatty acids (PUFA) and of data on the omega-3 PUFA treatment in patients with cardiovascular and kidney diseases.The major statements of the Expert Council: the meta-analysis of AF risk in patients taking omega-3 PUFA showed an increased risk of this arrhythmia. However, it should be taken into account that the risk of complications was low, and there was no significant increase in the risk of AF when omega-3 PUFA was used at a dose of ≤1 g and a standard dose of the only omega-3 PUFA drug registered in the Russian Federation, considering all AF episodes in the ASCEND study.At the present time, according to Russian and international clinical guidelines, the use of omega-3 PUFA can be considered in the following cases: • for patients with chronic heart failure (CHF) with reduced left ventricular ejection fraction as a supplement to the basic therapy (2B class of recommendations according to the 2020 Russian Society of Cardiology guidelines (RSC) and the 2022 AHA / ACC / HFSA guidelines); • for patients with hypertriglyceridemia (>1.5 mmol/l) as a part of combination therapy (IIb class of recommendations and B level of evidence according to the 2021 European guidelines on cardiovascular disease prevention, etc.); • for adult patients with stage 3-4 chronic kidney disease (CKD), long-chain omega-3 PUFA 2 g/day is recommended for reducing the level of triglycerides (2C class of recommendations). Data on the use of omega-3 PUFA for other indications are heterogenous, which can be partially explained by using different form and doses of the drugs.
    MeSH term(s) Adult ; Humans ; Stroke Volume ; Ventricular Function, Left ; Cardiovascular System ; Fatty Acids, Omega-3 ; Atrial Fibrillation/complications ; Atrial Fibrillation/drug therapy ; Renal Insufficiency, Chronic ; Russia/epidemiology
    Chemical Substances Fatty Acids, Omega-3
    Language Russian
    Publishing date 2023-02-28
    Publishing country Russia (Federation)
    Document type Meta-Analysis ; English Abstract ; Journal Article
    ZDB-ID 131029-x
    ISSN 0022-9040
    ISSN 0022-9040
    DOI 10.18087/cardio.2023.2.n2388
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top